Ascendis Pharma A/S Q4 2024 Earnings Report $151.53 +0.47 (+0.31%) As of 02/25/2025 04:00 PM Eastern Earnings HistoryForecast Ascendis Pharma A/S EPS ResultsActual EPS-$0.68Consensus EPS -$1.32Beat/MissBeat by +$0.64One Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual RevenueN/AExpected Revenue$115.06 millionBeat/MissN/AYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ4 2024Date2/12/2025TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptASND Earnings History Ascendis Pharma A/S Earnings HeadlinesAscendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 24 at 7:23 PM | markets.businessinsider.comAscendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 24 at 4:01 PM | globenewswire.comThe U.S. is About to Run Out of Money… Again.Treasury Warns America is Nearing Bankruptcy Discover the harmful impact on your retirement savings… February 26, 2025 | True Gold Republic (Ad)Evercore ISI Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockFebruary 20, 2025 | americanbankingnews.comAscendis Pharma price target raised to $180 from $175 at Morgan StanleyFebruary 18, 2025 | markets.businessinsider.comLeerink Partnrs Issues Optimistic Forecast for ASND EarningsFebruary 18, 2025 | americanbankingnews.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Price Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock Rally Upcoming Earnings Autodesk (2/27/2025)Canadian Imperial Bank of Commerce (2/27/2025)Dell Technologies (2/27/2025)Royal Bank of Canada (2/27/2025)Toronto-Dominion Bank (2/27/2025)CrowdStrike (3/4/2025)Arista Networks (3/4/2025)AutoZone (3/4/2025)Target (3/4/2025)Marvell Technology (3/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
